Azzalure is a mode of action when injected into the target muscle, Azzalure (botulinum toxin type A) binds to the presynaptic nerve endings, crosses the pre-synaptic nerve membrane and blocks release of the neurotransmitter acetylcholine. This results in a reversible, inhibition of neurotransmission at the neuromuscular junction of the injected muscles (1-5)
After injection in the glabellar muscles (corrugators and procerus), moderate to severe glabellar wrinkles are reduced.
The median time to onset of response is 2 to 3 days following treatment. An optimal effect was demonstrated for up to 4 months after injection. Some patients were still responders at 5 months. The treatment interval depends on the individual patient’s response after assessment. Treatment interval should not be more frequent than every 3 months (6-10). RSO
Potential risks associated with the use of Azzalure ®
The nature of the potential adverse reactions is consistent with the pharmacological action of botulinum toxin type A and the injection procedure. It can include injection site reactions, headaches or clinically detectable effects in the muscles adjacent to the target muscles injected. Every effort should be made to avoid injection of excess botulinum toxin (i.e. overdosing) which can bind to sites outside the target area (11-14) or very rarely lead to remote effect of botulinum toxin A.
Knowledge of facial anatomy, training on the injection of botulinum toxin A in the glabella, consideration of the patient’s goal, examination of the patient’s facial mimics and wrinkles and the use of Azzalure ® according to the recommendations in the SmPC, i.e., for dose, product reconstitution and injection sites, will optimise treatment effect and safety. The most frequently occurring adverse reactions are headache and injection site reactions. In general, treatment/injection technique related reactions occur within the week following the injection and are transient.